Navigation Links
Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
Date:8/29/2008

CRANBURY, N.J., Aug. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), today announced Chief Operating Officer Matthew Patterson will make a presentation at the BioCentury NewsMakers in the Biotech Industry Conference on Thursday, September 4, 2008 at 2:30 p.m. EDT in Room 402/403 with a breakout session immediately following the presentation in Room 401. The conference will be held at Millennium Broadway Hotel & Conference Center in New York.

A webcast and audio archive of the presentation will be available at http://www.amicustherapeutics.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's Web site for 30 days until October 4, 2008.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

FOLD-G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
2. Amicus Therapeutics Announces First Quarter 2008 Financial Results
3. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
5. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
6. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
9. Amicus Therapeutics to Host R&D Day
10. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...HANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is ...turmoil and uncertainty is part of many,businesses...stry has been,relatively immune to the economic do...,, During the midst of the difficult times ...Johnson inaugurated an R&D center in Shanghai,...
(Date:12/1/2009)...ILLAGE, Nev., Dec. 1 PDL...unced revenue guidance for the fourth quarter ende...as compared with $69 million for the fourth quarte... was the first of two installment payments of $12....uarter 2008 results was a one-time $1.8 million pa...
(Date:12/1/2009)..., Mass., Dec. 1 Harvest Technologi...esults from the company sponsored 60-patient clini...ter in Chennai, India using the company,s BMAC Sys...tical Limb Ischemia (CLI). Sri Ramachandra Medical...ted institution based in Chennai, India and one of...
(Date:12/1/2009)...TA, Fla., Dec. 1 Expanding its Eur...nics Inc. of Sarasota has appointed Lake Chemicals...Lake is located near Birmingham, England. ,, O...h serve the agricultural, waste water, and environ... and to open drain fields, and clean up industrial...
Breaking Biology Technology:Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3
...3 NOVIS Pharmaceuticals, Inc. today,announced tha...been,appointed Chairman of the Board. The appointm...rd of Directors meeting and is effective immediate...20081023/CLTH043LOGO ), "I am very excited to ta...lping the company achieve its aggressive strategic...
...l., Oct. 23 Opponents of Michigan,s stem,cell res...esterday using,the tragic and universally reprehen...on to stem cell research. This ad is replete with ...ture and regulatory environment for,stem cell rese...s straight., First, examine the Proposal 2 itself...
...ia, October 23 GlaxoSmithKline Biologicals,S.A. (...n of a,collaboration agreement granting GSK exclus...e programmes, aimed at treating Alzheimer,s by,tar...K is acquiring exclusive rights to develop,and com...tes that are based,on AFFiRiS AFFiTOPE technology ...
Other Biology Technology:NOVIS Announces Appointment of John J. Arlotta as Chairman 2Anti-Stem-Cell-Research Ad Ignores Facts 2Anti-Stem-Cell-Research Ad Ignores Facts 3GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimer's Disease Candidate Vaccines 2GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimer's Disease Candidate Vaccines 3
(Date:12/1/2009)...n a world first, a Monash University-led internati... to boost the output of the next generation of sol...collaboration with colleagues from the universitie...tandem dye-sensitised solar cells with a three-fol...d with previously reported tandem dye-sensitised s...
(Date:12/1/2009)... Antennas aren,t just for listening to the radio a...s to GPS devices. Research from North Carolina Sta...nna design creating shape-shifting antennas that ...ing from public safety to military deployment. , ...als, but there are limitations to how far they can...
(Date:11/30/2009)...he first comprehensive review of the state of Anta...l climate system is published this week (Tuesday 1...c Research (SCAR). The review - Antarctic Climate...esearch from the icy continent, identifies areas f...rgent questions that policy makers have about Anta...
Breaking Biology News(10 mins):Innovation puts next-generation solar cells on the horizon 2Shape shifters: Researchers create new breed of antennas 2First comprehensive review of the state of Antarctica's climate 2ULURU Discussions to Acquire York Pharma plc Are Currently Terminated 12776 1ULURU Discussions to Acquire York Pharma plc Are Currently Terminated 12776 2Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 4645 1Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 4645 2Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 4645 3Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 4645 4Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 4645 5Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 4645 6Migraine Frequency Tied to Stroke Heart Attack Risk 49976 1Migraine Frequency Tied to Stroke Heart Attack Risk 49976 2Migraine Frequency Tied to Stroke Heart Attack Risk 49976 3
...nternational GIANT (Genetic Investigation of Anthr...overy of obesity genes. So far, the scientists hav...-wide association studies with a total of more tha...date genes were validated in 14 further studies in...O and MC4R genes already known, it was now possibl...
...DELPHIA A study published in Cancer Prevention R...r Cancer Research, identifies components of black ...earchers at the Ohio State Comprehensive Cancer Ce...s in black raspberries, inhibited growth and stimu...ith an esophageal carcinogen. , "Our data provid...
...nzyme machine that translates a cell,s DNA code in...rial perfectionist. , Johns Hopkins researchers,...a new "proofreading step" during which the suite o...es errors, just after making them, and definitivel...tton. , It turns out, the Johns Hopkins researche...
Other Biology News:Obesity starts in the head? 6 newly discovered genes for obesity have a neural effect 2Lost in translation 2
...ker consists of ten double-stranded RNAs, 10, 20, ...rs. The dsRNA Marker is an ideal size marker for d...ty bp RNA band including in the dsRNA Marker is ad...ation. The dsRNA Marker is manufactured for non-de...
... size markers are a mixture of Strep•Tag®...e markers provide precise size references for prot...h Coomassie blue. Because each of the proteins con...can also be detected by the Strep•Tag II Mono...
Mouse Anti-Human ACP2 Monoclonal Antibody, Unconjugated, Clone M1-4A12 from Novus Biologicals
...er rocking platform, 220 V, is used for agitation ...on of liquid cultures, staining and destaining of ...cker features variable speed control (8-40 rpm) an... rocker features two 29 x 21 cm platforms covered ...
Biology Products: